July 21, 2021
11:00 am – 1:00 pm EDT
5:00 pm – 7:00 pm CET
Greg Russotti
Keynote Speaker
As part of the build-up for the ECI Advancing Manufacture of Cell and Gene Therapies conference that will be held in San Diego in February 2022, we are pleased to be hosting a special webinar to look at some of the key challenges facing our industry as we continue to grow and develop, providing a glimpse into some of the focus areas of the 2022 in-person conference.
The webinar, which was held on July 21, featured a keynote presentation by Greg Russotti followed by interactive panel sessions on the future perspectives for digitized manufacturing and real-time release and an open debate on the application of viral versus non-viral gene delivery technologies (more details on these sessions can be found below).
Webinar Presentation
Click to view the webinar presentation.
Conference Chairs
Sean Palecek, University of Wisconsin, USA
Damian Marshall, Achilles Therapeutics, UK
Fernanda Masri, Cell & Gene Therapy Catapult, UK
Sponsored By
Session Descriptions
Panel Session: “Future perspectives for digitized manufacturing and real-time release” With increasingly complex products requiring new techniques, our panelists will discuss their unique perspectives into manufacturing, monitoring, and analytics for product release. Our moderator, Greg Russotti, will prompt a discussion around the singularities and commonalities for autologous versus allogeneic products. Join the panel to learn more about these topics and the respective sessions that will take place in-person, in February 2022.
Panel:
- Moderator: Greg Russotti, Century Therapeutics
- Panelist (Cell Therapy Manufacturing): Masahiro Kino-oka, Osaka University
- Panelist (Big Data and Analytics): Angela Keightley, Bluerock Therapeutics
- Panelist (Product Release): Azadeh Golipour, Avro Bio
Debate Session: “The Future of Gene Therapy: Viral or Non-viral” The debate will engage webinar participants in a spirited discussion of the future of gene therapies, comparing and contrasting the advantages and drawbacks of viral and non-viral gene editing strategies, including safety, efficiency, and manufacturing considerations. Debaters will provide a short overview of their point of view then address questions from the audience and moderator. The concepts raised in the debate will provide webinar participants with an understanding of the state-of-the-art and current challenges in gene therapy, setting the stage for the Gene Therapy sessions for the in person workshop in February 2022.
Debate:
- Moderator: Mike Greene, iVexSol
- Debater (Viral): David Schaffer, University of California-Berkeley
- Debater (Non-viral): James Dahlman, Georgia Institute of Technology